Track Lakefront Biotherapeutics N.V. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Lakefront Biotherapeutics N.V. LKFT · Stock Open Lakefront Biotherapeutics N.V. in new tab

33.98 USD
P/E
3.30
EPS
10.52
P/B
12.42
ROE
20.12
Beta
0.01
Target Price
30.55 USD
Loading chart...
Key Metrics
Earnings dateFeb. 25, 2027
P/E3.30
EPS10.52
Book Value2.79
Price to Book12.42
Debt/Equity0.20
% Insiders25.447%
Growth
Revenue Growth-0.82%
Estimates
Forward P/E-29.12
Forward EPS-1.19
Target Mean Price30.55

DCF valuation

Model fair value for Lakefront Biotherapeutics N.V. (LKFT)
Result
Sign in to run the valuation for LKFT.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
3 analysts · consensus Hold · mean target 30.55 USD (low 21.05, high 44.93) · as of 12 Nov 2026
Low 21.05
Mean 30.55
High 44.93
Price 33.98
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Lakefront Biotherapeutics N.V. Logo Lakefront Biotherapeutics N.V. Analysis (LKFT)

Belgium Healthcare Official Website Stock

Is Lakefront Biotherapeutics N.V. a good investment? Lakefront Biotherapeutics N.V. (LKFT) is currently trading at 33.98 USD. Market analysts have a consensus price target of 30.55 USD. This suggests the asset is currently trading above analyst expectations.

In terms of valuation, the stock trades at a P/E ratio of 3.30. This relatively low multiple may signal that Lakefront Biotherapeutics N.V. is undervalued compared to historical market norms.

Earnings Schedule: Lakefront Biotherapeutics N.V. is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is -1.19.

Investor FAQ

Does Lakefront Biotherapeutics N.V. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Lakefront Biotherapeutics N.V.?

Lakefront Biotherapeutics N.V. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of 10.52.

Company Profile

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Exchange Ticker
NASDAQ LKFT
NMS (United States) GLPG
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion